Trial · NCT00053846
Buspirone in Reducing Shortness of Breath in Patients With Cancer
NCT00053846, Phase 2, Phase 3, Completed, University of Rochester; results first posted 2015-03-20
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Buspirone in Reducing Shortness of Breath in Patients With Cancer. Trials, record NCT00053846. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00053846
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Buspirone in Reducing Shortness of Breath in Patients With Cancer
- NCT number
- NCT00053846
- Status
- Completed
- Phases
- Phase 2, Phase 3
- Enrollment
- 432 participants, actual
- Lead sponsor
- University of Rochester
- Conditions
- Dyspnea, Pulmonary Complications, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- buspirone hydrochloride, Placebo
- First posted
- 2003-02-06
- Last updated
- 2015-11-24
- Results first posted
- 2015-03-20
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Dyspnea as Measured by Oxygen Cost Diagram (OCD) | 28 days after beginning study drug or placebo | OCD was used to evaluate dyspnea on exertion and activities of daily living. OCD is a visual analog scale for quantifying a patient's evaluation of tolerance of exertion, which corresponds to oxygen requirements at different activity levels. It is measured as a score of 2 (sleeping) to 14 (brisk walking uphill). HIgher scores indicate fewer limitations due to dyspnea. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Dyspnea as Measured by Oxygen Cost Diagram (OCD) | 28 days after beginning study drug or placebo | units on a scale | MEAN |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Dyspnea as Measured by Oxygen Cost Diagram (OCD) | Buspirone Hydrochloride | 8.98 | Standard Deviation 2.85 | units on a scale | |
| Dyspnea as Measured by Oxygen Cost Diagram (OCD) | Placebo | 9.32 | Standard Deviation 2.62 | units on a scale |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Buspirone Hydrochloride | 213 | |
| Overall Study | STARTED | Placebo | 219 | |
| Overall Study | COMPLETED | Buspirone Hydrochloride | 187 | |
| Overall Study | COMPLETED | Placebo | 192 | |
| Overall Study | NOT COMPLETED | Buspirone Hydrochloride | 26 | |
| Overall Study | NOT COMPLETED | Placebo | 27 |
Source ClinicalTrials.gov
Adverse events44
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Dizziness, confusion; insomnia | Nervous system disorders | Buspirone Hydrochloride | 2 | 213 | |
| other | Dizziness, confusion; insomnia | Nervous system disorders | Placebo | 2 | 219 | |
| other | GI Bleed | Gastrointestinal disorders | Buspirone Hydrochloride | 0 | 213 | |
| other | GI Bleed | Gastrointestinal disorders | Placebo | 1 | 219 | |
| other | Aching hands and back | General disorders | Buspirone Hydrochloride | 0 | 213 | |
| other | Aching hands and back | General disorders | Placebo | 1 | 219 | |
| other | Nausea and vomitting | Gastrointestinal disorders | Buspirone Hydrochloride | 3 | 213 | |
| other | Nausea and vomitting | Gastrointestinal disorders | Placebo | 1 | 219 | |
| other | Disease progression | General disorders | Buspirone Hydrochloride | 0 | 213 | |
| other | Disease progression | General disorders | Placebo | 1 | 219 |
1 to 10 of 44Source ClinicalTrials.gov
See all 44 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Buspirone Hydrochloride | ||
| Total, all-cause mortality | Placebo | ||
| Total, other adverse events | Buspirone Hydrochloride | 13 | 213 |
| Total, other adverse events | Placebo | 10 | 219 |
| Total, serious adverse events | Buspirone Hydrochloride | 3 | 213 |
| Total, serious adverse events | Placebo | 3 | 219 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| U10CA037420 | University of Rochester Cancer Center CCOP Research Base | MORROW, GARY R | UNIVERSITY OF ROCHESTER | NATIONAL CANCER INSTITUTE | 1985 to 2014 |
Source NIH RePORTER
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Buspirone Hydrochloride vs Placebo: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00053846
GET https://conductscience.org/api/trials/v1/NCT00053846/events?page=2